Redhill Biopharma (RDHL)
(Delayed Data from NSDQ)
$0.51 USD
+0.03 (6.75%)
Updated Mar 27, 2024 04:00 PM ET
After-Market: $0.52 +0.01 (1.54%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
RDHL 0.51 +0.03(6.75%)
Will RDHL be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for RDHL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RDHL
RedHill Biopharma (RDHL) Up on New Patent for COVID-19 Candidate
RedHill (RDHL) Up on Orphan Drug Tag for NTM Disease Drug
RDHL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Redhill Biopharma Ltd. (RDHL) Could Find Support Soon, Here's Why You Should Buy the Stock Now
Other News for RDHL
RedHill Biopharma Share Capital Increase Approved
RedHill Biopharma Reschedules Shareholders Meeting
RedHill Announces New USPTO Patent Covering Talicia® Through 2034
RedHill Biopharma announces new USPTO patent covering Talicia through 2034
RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs